Best Online Semaglutide Programs in 2026 (7 Providers Compared)

Why semaglutide matters for women in perimenopause and menopause

Weight gain in perimenopause is not simply a matter of eating more or moving less. Declining estrogen shifts the body's fat distribution toward the abdomen, slows resting metabolism, and disrupts appetite-regulating hormones — making the standard advice to eat less and exercise more genuinely harder to follow than it was at thirty. Semaglutide addresses part of that puzzle by mimicking the GLP-1 hormone your gut naturally produces after eating, slowing gastric emptying and dampening appetite signals in a way that makes calorie reduction feel less like willpower and more like biology. Clinical trials show roughly 15% average body weight loss over 68 weeks in adults on injectable semaglutide — and the weight that comes off tends to be preferentially abdominal, which is exactly where menopausal fat accumulates.

Semaglutide also has one of the best-studied safety profiles of any weight-loss medication. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events in adults with obesity and established cardiovascular disease. For women entering midlife, when cardiovascular risk starts to climb, that data point is more than a footnote. Semaglutide is not a hormone therapy and does not address hot flashes, sleep disruption, or vaginal symptoms directly — but for midlife women whose primary concern is metabolic weight, it is one of the most evidence-backed tools available.

Best compounded semaglutide online: Mochi Health

Mochi Health earns the top compounded slot because its pricing is genuinely flat. Most programs raise your monthly bill as you work through the standard titration schedule — 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg. Mochi charges the same $99 a month for the medication regardless of dose, and ships it to your door. The only add-on is a $79 monthly membership that covers provider visits, messaging, and care coordination — so the real standing cost is about $178 a month, which remains among the lowest verified all-in prices on this list.

What distinguishes Mochi from some competitors is format flexibility. Compounded semaglutide is available as a subcutaneous injection, an oral tablet, oral drops, and a microdose option — four choices, not one. The clinical team includes physicians with board certification in obesity medicine (ABOM), a credential that is rare even in specialty clinics. Mochi is available across all 50 states.

Two things to know before you enroll. First, the medication and membership are billed separately, and the dual-subscription model has generated complaints about billing transparency — read the cancellation terms carefully. Second, Mochi's primary pharmacy partner (Aequita) was shut down by Washington State in March 2025; verify the current compounding pharmacy in writing before you start.

• Pros — flat $99 medication at every dose; four semaglutide formats; ABOM-credentialed physicians; all 50 states; shipping included.
• Cons — $79/mo membership is a separate charge (real cost is $178/mo); dual-billing model has generated BBB complaints; verify current compounding pharmacy.

Other compounded semaglutide programs worth comparing

Henry Meds — bundled, no membership, oral or injection

Henry Meds is one of the most established names in compounded GLP-1 telehealth. Its pricing is genuinely all-in: oral semaglutide runs $249 a month and the injectable runs $297 a month, each bundling the medication, provider visits, supplies, and shipping into a single line item. There is no separate membership fee to track alongside the medication charge. For someone who dislikes the dual-billing structure of Mochi, Henry Meds is a clean alternative — you know what you owe each month from day one.

Henry Meds is particularly useful if you prefer swallowing a tablet to self-injecting. The oral compounded semaglutide at $249 a month is a meaningful savings over the injectable, and oral delivery is just as effective for most patients at the doses available. Henry Meds is available in approximately 41 states.

• Pros — truly all-in pricing with no membership; oral and injectable options; large, established platform; ~41 states.
• Cons — injectable ($297/mo) costs more than Mochi's all-in ($178/mo); annual prepay option may lock you in before you know how you respond.

Eden — lowest intro price, simple structure

Eden offers one of the more accessible entry points: roughly $199 to $249 for the first month, with ongoing rates running $279 to $299 a month depending on the plan. There is no membership fee, and the price holds flat across doses. For someone who wants to test compounded semaglutide before committing to a longer program, the lower first-month cost and no-contract flexibility make Eden worth pricing alongside Mochi and Henry Meds.

• Pros — lower intro month; no membership fee; flat price across all doses; month-to-month option.
• Cons — ongoing price of $279–$299/mo is higher than Mochi's all-in $178/mo; verify which pharmacy source (503A vs 503B) given the April 2026 FDA proposal.

Hers — oral and injectable, with a major caveat to check

Hers (the women's health arm of Hims & Hers) offers compounded semaglutide in both oral and injectable formats, with prices in the $199 to $299 range depending on format and plan length. No separate membership fee. The platform is well-designed and has broad name recognition. The critical thing to verify before signing up: in March 2026, Hims & Hers reached an agreement with Novo Nordisk to transition compounded patients to brand-name Ozempic or Wegovy. The status of Hers compounded semaglutide may have changed since this page was written. Confirm directly with the platform whether compounded is still available before you enroll.

• Pros — oral and injectable formats; no separate membership; familiar platform for women's telehealth.
• Cons — March 2026 Novo Nordisk agreement may have ended or restricted compounded availability; verify current status before signing up.

Willow — flat rate, LegitScript certified, 33 states

Willow charges a flat $299 a month for compounded semaglutide at every dose, with medication, physician access, and free two-day shipping included. No membership fee, no titration hikes. The platform is LegitScript certified — a third-party legitimacy credential that relatively few telehealth programs hold — and prescribes through a named California medical group with a publicly listed US address. For a woman who wants a verified pharmacy track record and a predictable, one-number bill at maintenance dose, Willow is competitive even at $299 a month. The only limiting factor is geography: Willow is available in approximately 33 states.

• Pros — LegitScript certified; flat $299 at every dose; no membership; free two-day shipping; injection and oral tablet formats.
• Cons — only ~33 states; $299/mo is higher than Mochi all-in ($178) and Henry Meds oral ($249); check state availability before starting.

WeightWatchers (Sequence) — best if insurance is your path

WeightWatchers acquired Sequence (now operating as WW Clinical) specifically to help members navigate insurance coverage for brand-name GLP-1 medications. The membership runs $99 to $149 a month and covers access to a licensed telehealth prescriber, labs, and a team focused on prior-authorization support — but medication cost is separate and depends on your insurance plan. If you have commercial insurance and qualify for Wegovy coverage (BMI 30 or higher, or 27 with a comorbidity), Sequence can meaningfully reduce your out-of-pocket cost. If you are cash-pay only, the separate medication cost on top of the membership makes other programs more competitive.

• Pros — strong insurance navigation; prescribes brand-name Wegovy (FDA-approved); WW behavioral program also included.
• Cons — membership fee is on top of medication cost; not the right fit if you are cash-pay and do not have usable insurance coverage.

Brand-name Wegovy: the FDA-approved alternative

Every compounded semaglutide program on this list produces a pharmacy-mixed version of the molecule — not the FDA-approved finished drug. Brand-name Wegovy (the injectable pen) and the newly approved oral Wegovy tablet (approved December 2025) are the regulated products, manufactured by Novo Nordisk to consistent pharmaceutical standards with known supply chains and FDA-reviewed safety data. At retail without insurance, Wegovy runs $1,349 or more per month — a price that makes cash-pay compounded programs look cheap by comparison.

The insurance picture is different. Many commercial plans cover Wegovy for patients who meet BMI criteria (30 or higher, or 27 with a qualifying comorbidity). Starting July 2026, Medicare Part D is expected to cover branded GLP-1s for weight management for eligible enrollees. If you have coverage that includes Wegovy, the brand-name option may cost you less out of pocket than any compounded program — and comes without the regulatory uncertainty. Run the numbers on your specific plan before defaulting to compounded.

• Brand-name Wegovy is FDA-approved; compounded semaglutide is not FDA-approved as a finished product — the manufacturing review differs.
• Any provider calling compounded semaglutide 'generic Wegovy' or 'FDA-approved compound' is misstating it: compounded drugs are not FDA-approved by definition.
• Injectable Wegovy retail runs $1,349+/mo without insurance; with coverage and a savings card, out-of-pocket cost may be $25–$99/mo for eligible patients.
• The oral Wegovy pill (25 mg once-daily tablet, FDA-approved December 22, 2025) is brand-name only — there is no compounded oral semaglutide equivalent that is FDA-approved.

Compounded semaglutide: what the rules actually say in mid-2026

The legal footing for compounded semaglutide has narrowed since 2025, but it has not collapsed. The FDA declared the semaglutide shortage resolved on February 21, 2025. That resolution removed the primary exception that allowed 503B outsourcing facilities — larger-scale, federally registered compounders — to produce semaglutide in bulk for broad distribution. On April 30, 2026, the FDA went further, proposing to formally remove semaglutide (along with tirzepatide and liraglutide) from the 503B bulks list entirely. That proposed rule was in public comment through June 29, 2026 and had not been finalized as of this writing.

What remains legal after these changes is 503A compounding: state-licensed pharmacies that mix medication for specific, identified patients under a valid prescription from a licensed prescriber. Every program on this list sources from 503A pharmacies. The 503A pathway requires that a licensed clinician determine there is a clinical reason to compound for a particular patient — a reasonable standard that legitimate telehealth programs can meet. That said, the regulatory environment is actively in motion, and programs that are fully compliant today could face supply or compliance changes in the months ahead. Ask any provider directly which licensed 503A pharmacy fills your prescription, and request a Certificate of Analysis for the batch.

• 503A compounding for individual patients under a valid prescription is still legal in mid-2026.
• 503B bulk compounding of semaglutide is facing a proposed FDA ban (not yet finalized as of June 29, 2026 comment-period close).
• The FDA received over 455 adverse-event reports linked to compounded semaglutide by early 2025 — many involving dosing errors from unlabeled or improperly labeled vials.
• Ask for the name of the compounding pharmacy and a Certificate of Analysis before you start any compounded program.

How to choose: a decision guide for midlife women

The right program depends on what you are actually optimizing for. Price is rarely one number — factor in the membership, the per-dose escalation (or lack of it), the billing cycle, and the prepayment terms before you compare headlines. Here is a short framework.

• Lowest verified all-in price across all doses with no surprise hikes: Mochi Health (~$178/mo, flat).
• Truly one-line bundled pricing with no membership: Henry Meds (oral $249/mo or injectable $297/mo).
• Lowest intro price with no long commitment: Eden (~$199–$249 first month, $279–$299 ongoing).
• LegitScript-certified flat rate in 33 states: Willow ($299/mo).
• Insurance navigation for brand-name Wegovy: WeightWatchers Sequence ($99–$149/mo membership, medication cost depends on your plan).
• You have insurance that covers Wegovy: run the numbers on brand-name before any compounded option.

One thing applies to every choice: semaglutide is a tool, not a complete solution. Perimenopausal and postmenopausal weight gain has a hormonal dimension that GLP-1 medications address indirectly at best. If you are also dealing with hot flashes, sleep disruption, or mood changes, talk to your provider about whether hormone therapy alongside semaglutide might serve you better than either alone. Emerging research suggests the combination may meaningfully amplify weight-loss outcomes.